Gastrointestinal stromal tumors;Tumeurs stromales gastro-intestinales

Presse Medicale

Volumn 41, Issue 10, 2012, Pages 917-926

  Sekkate, Sakina ^a   Kairouani, Mouna ^a   Abahssain, Halima ^a   Serji, Badr ^b   Boutayeb, Saber ^a   Mrabti, Hind ^a   Errihani, Hassan ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TUMOR MARKER;

CANCER ADJUVANT THERAPY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SURGERY; GENE MUTATION; HUMAN; INTERSTITIAL CELL OF CAJAL; METASTASIS POTENTIAL; ONCOGENE; ONCOGENE C KIT; PDFR GENE; SHORT SURVEY; STANDARD; TUMOR LOCALIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIAGNOSIS, DIFFERENTIAL; DIGESTIVE SYSTEM SURGICAL PROCEDURES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MOLECULAR TARGETED THERAPY; PROGNOSIS;

EID: 84866348310     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2011.11.020     Document Type: Short Survey

References (71)

1. Blay J.Y., Landi B., Bonvalot S., et al. Recommendations for the management of GIST patients. Bull Cancer 2005, 92(10):907-918.
2. Sanders K.M., Ward S.M. Interstitial cells of Cajal: a new perspective on smooth muscle function. J Physiol 2006, 576:721-726.
3. Kindblom L.G., Meis-Kindbolm J., Bumming P., et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal cell tumors (GIST) - a population-based study of 600 cases. Ann Oncol 2002, 13(Suppl. 5):157. [Abstr Book of the 27th ESMO Congr].
4. Benesch M., Wardelmann E., Ferrari A., et al. Gastrointestinal stromal tumors (GIST) in children and adolescents: a comprehensive review of the current literature. Pediatr Blood Cancer 2009, 53:1171-1179.
5. Liegl-Atzwanger B., Fletcher J.A., Fletcher C.D. Gastrointestinal stromal tumors. Virchows Arch 2010, 456(2):111-127.
6. Duensing S., Duensing A. Targeted therapies of gastrointestinal stromal tumors (GIST)-The next frontiers. Biochem Pharmacol 2010, 80:575-583.
7. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
8. Chen H., Hirota S., Isozaki K., et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 2002, 51(6):793-796.
9. Theou-Anton N., Tabone S., Brouty-Boye D., Saffroy R., Ronnstrand L., Lemoine A., Emile J.F. Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism. Br J Cancer 2006, 94(8):1180-1185.
10. Heinrich M.C., Corless C.L., Duensing A., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003, 299(5607):708-710.
11. Emilea J.F., Bacheta J.B., Tabone-Eglingerd S., Brahimia S. Histologie et pathologie moléculaire des tumeurs stromales gastrointestinales. Rev Fr Lab 2008, No. 398.
12. Taylor BS, Barretina J, Maki RG, et al. Advances in sarcoma genomics and new therapeutic targets. 2011;11:541-57.
13. Bui B.N., Stoeckle E., Kind M., Coindre J.M. Tumeurs stromales du tube digestif (GIST). Oncologie 2007, 9:144-151.
14. Demetri G.D. NCCN Task update on the management of patients with GIST. J Natl Compr Canc Netw 2010, 8(Suppl. 2):S1-S41.
15. Tumeurs stromales gastro-intestinales (GIST). Thésaurus national de cancérologie digestive 2010. http://www.snfge.com/.
16. Dei Tos A.P., Laurino L., Bearzi I., Messerini L., Farinati F. Gastrointestinal stromal tumors: the histology report. Dig Liver Dis 2011, 43S:S304-S309.
17. Chu-Chung C., Ming-Jen C., Chin-Yuan T. Prediction of KIT mutation in gastrointestinal stromal tumors by the immunoprofile of the tumor cells. J Formos Med Assoc 2010, 109(1):25-31.
18. Suster S. Gastrointestinal stromal tumors. Semin Diagn Pathol 1996, 13:297-313.
19. Conlon K.C., Casper E.S., Brennan M.F. Primary gastrointestinal sarcomas: analysis of prognostic variables. Ann Surg Oncol 1995, 2:26-31.
20. Balaton A.J., Coindre J.M., Cvitkovic F. Tumeurs stromales digestives. Gastroenterol Clin Biol 2001, 25:473.
21. Lewin K.J., Appelman H.D. Tumors of the esophagus and stomach. Atlas of Tumor Pathology. Third Series Fascicle 18 1995, AFIP, Washington, DC.
22. Ng E., Pollock R., Romsdahl M. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992, 69:1334-1341.
23. Burkill G., Badran M., Al-Muderis O., et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread. Radiology 2003, 226:527-532.
24. Alberini J.L., Al Nakib M., Wartski M., et al. Place de l'imagerie par tomographie par émission de positons pour les tumeurs stromales gastro-intestinales. Gastroenterol Clin Biol 2007, 31:585-593.
25. Taïeb S., Ceugnart L., Bonodeau1 F., Vanseymortier L., Adenis A. GIST : rôle de l'imagerie. J Chir 2008, 145(Supplément 3):12-17.
26. Verweij J., Casali P.G., Zalcberg J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364(9440):1127-1134.
27. Choi H., Charnsangavej C., de Castro Faria S., et al. CT evaluation of the response of gastrointestinal STromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol 2004, 183(6):1619-1628.
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in OncologyTM: Soft Tissue Sarcoma. http://www.nccn.org/index.asp.
29. Fletcher C.D., Berman J.J., Corless C., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002, 33(5):459-465.
30. Miettinen M., Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006, 23:70-83.
31. Martin-Broto J., Gutierrez A., Garcia-del-Muro X., et al. Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study. Ann Oncol 2010, 21(7):1552-1557.
32. Gold J.S., Gönen M., Gutiérrez A., et al. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol 2009, 10(11):1045-1052.
33. Hohenberger, Eisenberg B. Role of surgery combined kinase inhibition in the management of GIST. Ann Surg Oncol 2010, 17(10):2585-2600.
34. Landi B. Tumeurs stromales gastro-intestinales (GIST) de taille limitée (inférieure à 5cm) : revue de la littérature et propositions pour la prise en charge. Gastroenterol Clin Biol 2010, 34(2):120-133.
35. Blesius A., Cassier P.A., Bertucci F., et al. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial. BMC Cancer 2011, 11:72.
36. Hohenberger P., Eisenberg B. Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST). Ann Surg Oncol 2010, 17:2585-2600.
37. Aparicio T., Boige V., Sabourin J.C., Crenn P., Ducreux M., Le Cesne A., et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004, 30:1098-1103.
38. Adam R., Chiche L., Aloia T., et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg 2006, 244:524-535.
39. Raut C.P., Posner M., Desai J., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006, 24:2325-2331.
40. Blay J.Y. A decade of tyrosine kinase inhibitor therapy: historical and current perspectives on targeted therapy for GIST. Cancer Treat Rev 2011, 37:373-384.
41. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
42. Carroll M., Ohno-Jones S., Tamura S., et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
43. Buchdunger E., Zimmermann J., Mett H., et al. Inhibition of the Abl protein- tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996, 56:100-104.
44. Heinrich M.C., Griffith D.J., Druker B.J., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000, 96:925-932.
45. Joensuu H., Roberts P.J., Sarlomo-Rikala M., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001, 344:1052-1056.
46. van Oosterom A.T., Judson I., Verweij J., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001, 358:1421-1423.
47. Verweij J., Van Oosterom A., Blay J.Y., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003, 39:2006-2011.
48. Doi T., Nishida T., Hirota T., et al. Phase II clinical study of STI571 in Japanese (Jpn) patients (pts) with malignant gastrointestinal stromal tumors (GIST): results of the B 1201 study. J Clin Oncol 2004, 22(14S):4078.
49. Nishida T., Shirao K., Sawaki A., et al. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol 2008, 13:244-251.
50. Blanke C.D., Demetri G.D., von Mehren M., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008, 26:620-625.
51. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480.
52. von Mehren M., Heinrich M.C., Joensuu H., et al. Follow-up results after 9years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). J Clin Oncol 2011, 29. [Suppl.: abstr 10016].
53. Dagher R., Cohen M., Williams G., et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002, 8:3034-3038.
54. European Medicines Association. Glivec: European Public Assessment Report; 2001.
55. The Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST) Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1640 patients. J Clin Oncol 2010, 28:1247-1253.
56. Casali P.G., Blay J.Y. On behalf of the ESMO Guidelines Working Group. Gastrointestinal stromal tumours: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v98-v102.
57. Blay J.Y., Le Cesne A., Ray-Coquard I., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007, 25:1107-1113.
58. Ray-Coquard I.L., Bin Bui N., Adenis A., et al. Risk of relapse with imatinib (IM) discontinuation at 5years in advanced GIST patients: results of the prospective BFR14 randomized phase III study comparing interruption versus continuation of IM at 5years of treatment: a French Sarcoma Group Study. J Clin Oncol 2010, 28:15s. [Suppl.: abstr 10032].
59. Zalcberg J.R., Verweij J., Casali P.G., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 2005, 41:1751-1757.
60. Dematteo R.P., Ballman K.V., Antonescu C.R., et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373:1097-1104.
61. European Medicines Association. Annex I: summary of product characteristics. Accessed November 8, 2010.
62. US Food and Drug Administration. Committee for medicinal products for human use post-authorisation summary of positive opinion for Glivec. ; 2008. Accessed June 1, 2010. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm129210.htm.
63. Joensuu H., Eriksson M., Hatrmann J., et al. Twelve versus 36 months of adjuvant imatinib (IM) as treatment of operable GIST with a high risk of recurrence: final results of a randomized trial (SSGXVIII/AIO). J Clin Oncol 2011, 29. [abstr LBA1].
64. Eisenberg B.L., Harris J., Blanke C., George D. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009, 99(1):42-47.
65. McAuliffe J.C., Hunt K.K., Lazar A.J., et al. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol 2009, 16(4):910-919.
66. Demetri G.D., van Oosterom A.T., Garrett C.R. and al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368(9544):1329-1338.
67. George S., Blay J.Y., Casali P.G., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009, 45(11):1959-1968.
68. Casali P.G., Joensuu H., Broto J.M. Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol 2010, 28:15s. [abstr TPS332].
69. Kindler H.L., Campbell N.P., Wroblewski K., et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago Phase II Consortium trial. J Clin Oncol 2011, 29. [abstr 10009].
70. Blay A., Le Cesne N., Bui B., et al. Overall survival benefit with masitinib mesylate in imatinib-naive, locally advanced, or metastatic gastrointestinal stromal tumor (GIST): 4-year follow-up of the French Sarcoma Group phase II trial. J Clin Oncol 2011, 29. [abstr 85].
71. Demetri G.D. Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors. Semin Oncol 2011, 38(Suppl. 1):S10-S19.